(2S,3R,4R,5S)-4,5-bis(acetyloxy)-2-(3-ethyl-5-isoxazolyl)tetrahydro-3-furanyl acetate | 235744-80-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3R,4R,5S)-4,5-bis(acetyloxy)-2-(3-ethyl-5-isoxazolyl)tetrahydro-3-furanyl acetate
• 英文别名: acetic acid 4R,5S-diacetoxy-2S-(3-ethyl-isoxazol-5-yl)-tetrahydro-furan-3R-yl ester；[(2S,3R,4R,5S)-4,5-diacetyloxy-2-(3-ethyl-1,2-oxazol-5-yl)oxolan-3-yl] acetate
• CAS: 235744-80-6
• 化学式: C₁₅H₁₉NO₈
• 分子量: 341.318
• InChiKey: PYXSGRWTOXYNKB-KBUPBQIOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (2S,3R,4R,5R)-4,5-bis(acetyloxy)-2-(3-ethyl-5-isoxazolyl)tetrahydro-3-furanyl acetate 、 (2S,3R,4R,5S)-4,5-bis(acetyloxy)-2-(3-ethyl-5-isoxazolyl)tetrahydro-3-furanyl acetate 、 2,6-二氯嘌呤 在 三氟甲磺酸三甲基硅酯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 生成 Acetic acid 4R-acetoxy-2R-(2,6-dichloro-purin-9-yl)-5S-(3-ethyl-isoxazol-5-yl)-tetrahydro-furan-3R-yl ester
  参考文献：
  名称：

  Adenosine derivatives

  摘要：

  式（I）的化合物，该化合物是腺苷A1受体的激动剂，其中Y、Z和W代表杂原子，以及其盐和溶剂合物，特别是用于治疗的生理上可接受的溶剂合物和盐。

  公开号：

  US06492348B1

文献信息

• Purine derivatives
  申请人：Pfizer Inc

  公开号：US06624158B2

  公开（公告）日：2003-09-23

  The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, wherein R2 is —CH2NHSO2—A—R3, —CONR10—A1—R11, —X—NR12a—Y—NR13R14 or —CO—NR18—X1—NR12—Y—NR13R14; R19, where R19 is a C-linked, 5-membered aromatic heterocycle containing either (i) from 1 to 4 ring nitrogen atoms or (ii) 1 or 2 ring nitrogen atoms and 1 oxygen or 1 sulphur ring atom, said heterocycle being optionally substituted by C1-C6 alkyl, said C1-C6 alkyl being optionally substituted by phenyl, —OH, C1-C6 alkoxy or —NR20R21 and R1, A, R3, R10, R11, X, R12a, Y, R13, R14, R18, X1, R21 and R22 are as defined in the specification. The invention also relates to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists. The invention is particularly related to methods of treating respiratory diseases such as adult respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema bronchiectasis, chronic sinusitis and rhinitis.

  本发明涉及公式化合物及其药学可接受的盐和溶剂化物，其中R2为—CH2NHSO2—A—R3，—CONR10—A1—R11，—X—NR12a—Y—NR13R14或—CO—NR18—X1—NR12—Y—NR13R14; R19，其中R19为含有5个成员的C-连接芳香杂环，包含（i）1至4个环氮原子或（ii）1或2个环氮原子和1个氧或1个硫环原子，该杂环可被C1-C6烷基取代，该C1-C6烷基可被苯基，—OH，C1-C6烷氧基或—NR20R21取代，R1，A，R3，R10，R11，X，R12a，Y，R13，R14，R18，X1，R21和R22的定义如说明书所述。该发明还涉及制备该化合物所用的中间体的制备方法，以及含有这种化合物的组合物和这种化合物作为腺苷A2a受体激动剂的用途。该发明特别涉及如成人呼吸窘迫综合症，支气管炎，慢性支气管炎，慢性阻塞性肺疾病，囊性纤维化，哮喘，肺气肿支气管扩张症，慢性鼻窦炎和鼻炎等呼吸系统疾病的治疗方法。
• PURINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：EP1317465A1

  公开（公告）日：2003-06-11
• US6624158B2
  申请人：——

  公开号：US6624158B2

  公开（公告）日：2003-09-23
• [EN] PURINE DERIVATIVES<br/>[FR] DERIVES DE PURINE
  申请人：PFIZER LTD

  公开号：WO2002022630A1

  公开（公告）日：2002-03-21

  The present invention relates to compounds of formula (I) and phamaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of , and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.
• [EN] DIHYDROISOXAZOLYL SUBSTITUTED TETRAHYDROFURAN COOMPOUNDS AS INTERMEDIATES IN THE PREPARATION OF 2-(PURIN-9-YL) - TETRAHYDROFURAN DERIVATIVES<br/>[FR] COMPOSES DE TETRAHYDROFURAN DE DIHYDROISOXAZOLYLE SUBSTITUES UTILISES EN TANT QU'INTERMEDIAIRE DANS LA PREPARATION DE DERIVES DE 2-(PURINE-9-YL) - TETRAHYDROFURAN
  申请人：GLAXO GROUP LTD

  公开号：WO2003080604A1

  公开（公告）日：2003-10-02

  Dihydroisoxazolyl substituted Tetrahydrofuran compounds as intermediates in the preparation of 2 (puxin-9-y1)-tetrahydrofuran derivatives A process for preparing a compound of formula (I) which comprises dehydration of a compound of formula (II) according to Step (i): wherein R1 represents methyl, ethyl, -CH=CP2, n-propyl, -CH2FH=CH2, -CH=CHCH3, isopropyl, isopropenyl, cyclopropyl, cyclopropenyl, cyclôpropylmethyl, cyclopropenylmethyl, -CH (OH) CH3, - (CH2) q halogen, - (CH 2) hY (CH2) iH, - (CH2) kZ, - (CH2)hCO(CH2)oH, - (CH2)rS (O) t (CH2) sH or - (CH 2 )kC( (CH2)uH)=NO(CH2)vH; wherein Y represents O, S or NH (CH2)j; Z represents -COO(CH2)1H or -CON (CH2)mH((CH2)nH); q represents an intégér 0 to 3; h represents an integer 0 to 2; i represents an integer 0 to 2 such that h+i is in the range 0 to 3; j represents an integer 0 to 2 such that h+i+j is in the range 0 to 3; k represents 0 or 1; 1 represents 1 or 2, such that k+ 1 is in the range 1 to 2; m and n independently represent an integer 0 to 2 such that k+m+n is in the range 0 to 2; o represents an integer 0 to 2 such that h+o is in the range 0 to 2; r and s independently represent 1 or 2 such that r+s is in the range 2 to 3; t represents 1 or 2; u and v independently represent 0 or 1 such that k+u+v is in the range O to 1; L1 and L2 represent hydroxy or a protected derivative' thereof; and L3 represent a leaving group.